MAY 10, 2017
Glaucoma, IOP and Aqueous Flow, Surgical Management
Cyclophotocoagulation (CPC) is an effective form of cycloablative therapy, but it has been historically associated with numerous risks and considered a treatment of last resort. In this interview from AGS 2017, Dr. Jonathan Myers discusses the Micropulse (Iridex), a new transscleral diode laser CPC platform that appears to have a better safety profile than its predecessor. At the meeting, the 10 posters on the Micropulse showed good pressure reduction and success rates ranging from 50% to 80%. The incidence of reported side effects was low, with cystoid macular edema and loss of ≥2 lines of BCVA the most common.